Editorial

Editorial

Contenido principal del artículo

Pedro Luis Ramos

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Referencias (VER)

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. [Internet]. Clin Infect Dis. 2011;52:e56. Disponible en: https://doi.org/10.1093/cid/cir073

Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. [Internet]. N Engl J Med. 1971;284:1061. Disponible en: https://doi.org/10.1056/NEJM197105132841904

Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. [Internet]. JClinOncol. 1992;10:316. Disponible en: https://doi.org/10.1200/JCO.1992.10.2.316

Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. [Internet]. Support Care Cancer. 2004;12:555. Disponible en: https://doi.org/10.1007/s00520-004-0614-5

Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. [Internet]. J Clin Oncol. 2015;33:465. Disponible en: https://doi.org/10.1200/JCO.2014.57.2347

Ramos P, Sánchez R, Gamboa Ó, Cardona AF. Factores pronósticos relacionados con la mortalidad en pacientes con cáncer y neutropenia febril. [Internet]. RevColHematolOncol 2012;1(4):15–22. Disponible en: https://doi.org/10.51643/RevColHemOnc

Citado por